Paper8167351
A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group.
Ringdén O and 9 others. Blood, 1994. Cited by 290 papers, by iCite.
Cite this record
ConductScience Library. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Papers, record 8167351. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8167351
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group.
- PubMed
- Publication types
- Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bone Marrow Transplantation | Major topic |
| Busulfan | Major topic |
| Leukemia | Major topic |
| Whole-Body Irradiation | Major topic |
| Adolescent | |
| Adult | |
| Cause of Death | |
| Child | |
| Child, Preschool | |
| Cystitis | |
| Cytomegalovirus Infections | |
| Graft vs Host Disease | |
| Hepatic Veno-Occlusive Disease | |
| Humans | |
| Middle Aged | |
| Recurrence |
Source PubMed
Cited by104
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 290 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41713515 | Incorporating Intensity Modulated Total Body Irradiation (IMRT-TBI) Into Future Cooperative Group Clinical Trials: An NRG Hematologic Malignancies Working Group-Led Report From the National Clinical Trials Network. | Int J Radiat Oncol Biol Phys | 2026 | https://conductscience.org/library/papers/41713515 | PubMed |
| 40399957 | Improving total bone marrow and lymphoid irradiation: feasibility of intensity-modulated proton therapy (IMPT) and dosimetric comparison with helical tomotherapy (HT). | Radiat Oncol | 2025 | https://conductscience.org/library/papers/40399957 | PubMed |
| 36505853 | Conditioning regimens for allogeneic hematopoietic cell transplantation in acute myeloid leukemia: Real-world data from the Japanese registry studies. | Front Oncol | 2022 | https://conductscience.org/library/papers/36505853 | PubMed |
| 36263219 | Total marrow irradiation (TMI): Addressing an unmet need in hematopoietic cell transplantation - a single institution experience review. | Front Oncol | 2022 | https://conductscience.org/library/papers/36263219 | PubMed |
| 36084276 | Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/36084276 | PubMed |
| 35924145 | Feasibility of a Novel Sparse Orthogonal Collimator-Based Preclinical Total Marrow Irradiation for Enhanced Dosimetric Conformality. | Front Oncol | 2022 | https://conductscience.org/library/papers/35924145 | PubMed |
| 35242706 | Role of Radiation Based Conditioning Regimens in Patients With High-Risk AML Undergoing Allogenic Transplantation in Remission or Active Disease and Mechanisms of Post-Transplant Relapse. | Front Oncol | 2022 | https://conductscience.org/library/papers/35242706 | PubMed |
| 34956984 | Total Body Irradiation Forever? Optimising Chemotherapeutic Options for Irradiation-Free Conditioning for Paediatric Acute Lymphoblastic Leukaemia. | Front Pediatr | 2021 | https://conductscience.org/library/papers/34956984 | PubMed |
| 34513689 | Pulmonary Toxicity After Total Body Irradiation - Critical Review of the Literature and Recommendations for Toxicity Reporting. | Front Oncol | 2021 | https://conductscience.org/library/papers/34513689 | PubMed |
| 34501237 | The Role of Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Leukemia. | J Clin Med | 2021 | https://conductscience.org/library/papers/34501237 | PubMed |
| 33650334 | Current Use of Total Body Irradiation in Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation. | J Korean Med Sci | 2021 | https://conductscience.org/library/papers/33650334 | PubMed |
| 33544322 | Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care. | Int J Hematol | 2021 | https://conductscience.org/library/papers/33544322 | PubMed |
| 33458277 | Total marrow irradiation for hematopoietic malignancies using volumetric modulated arc therapy: A review of treatment planning studies. | Phys Imaging Radiat Oncol | 2019 | https://conductscience.org/library/papers/33458277 | PubMed |
| 33054792 | Leaf open time sinogram (LOTS): a novel approach for patient specific quality assurance of total marrow irradiation. | Radiat Oncol | 2020 | https://conductscience.org/library/papers/33054792 | PubMed |
| 32892216 | Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. | Bone Marrow Transplant | 2021 | https://conductscience.org/library/papers/32892216 | PubMed |
| 31675173 | Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan-Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation. | Clin Transl Sci | 2020 | https://conductscience.org/library/papers/31675173 | PubMed |
| 31647022 | Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. | J Hematol Oncol | 2019 | https://conductscience.org/library/papers/31647022 | PubMed |
| 31536825 | Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center. | Biol Blood Marrow Transplant | 2020 | https://conductscience.org/library/papers/31536825 | PubMed |
| 31473319 | Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. | Biol Blood Marrow Transplant | 2019 | https://conductscience.org/library/papers/31473319 | PubMed |
| 30099836 | Energy-dependent OAR sparing and dose conformity for total marrow irradiation of obese patients. | J Appl Clin Med Phys | 2018 | https://conductscience.org/library/papers/30099836 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8167351
GET https://conductscience.org/api/papers/v1/8167351/cited_by?page=2